Publication: Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers
Issued Date
2009-01-01
Resource Type
ISSN
09461965
DOI
Other identifier(s)
2-s2.0-70349899121
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Clinical Pharmacology and Therapeutics. Vol.47, No.9 (2009), 579-586
Suggested Citation
S. Kongpatanakul, S. Chatsiricharoenkul, A. Khuhapinant, S. Atipas, J. Kaewkungwal Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. International Journal of Clinical Pharmacology and Therapeutics. Vol.47, No.9 (2009), 579-586. doi:10.5414/CPP47579 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28257
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers
Other Contributor(s)
Abstract
Objective: As part of new drug development initiatives in Thailand, a new tablet formulation of dihydroartemisinin (DHA, an antimalarial drug) has been developed. Our previous bioequivalence study indicated that the new and reference DHA formulations were well tolerated; however, a significant decrease in hemoglobin was detected after a single 200-mg oral dose. To explore further, a clinical study with an emphasis on hematological parameters was conducted. Methods: A single-center, randomized, single-blind, cross-over clinical study was conducted in 18 healthy volunteers with a dosage of 300 mg daily for 2 days. Artesunate was used as a comparator. Adverse events were monitored and laboratory parameters on study Days 0, 2, 5, and 7 post drug administrations were analyzed. Results: Eighteen volunteers completed both rounds of the study. Both drugs were well tolerated. All adverse events were mild. Significant decrease in hemoglobin compared to baseline was detected for both drugs 7 days after administration (DHA: 0.48 g/dl, p = 0.007; artesunate 0.38 g/dl, p = 0.001). Transient bone marrow suppression was evidenced by reduction of reticulocytes with a lowest number on study Day 5 (artesunate 75% reduction in reticulocyte count; DHA47%, p <0.001 for both drugs compared to baseline). Conclusion: The present study confirmed our previous finding on significant decrease in hemoglobin. Artesunate appeared to have more negative effects on the numbers of reticulocytes and white blood cells than DHA. Systemic laboratory and toxicity profiles presented in this study may be used as a framework for future clinical studies of artemisinin and its derivatives. © 2009 Dustri-Verlag Dr. K. Feistle.